Clinical Trials

17 enrolled 14 charts

Breast Neoplasms

NCT03738553 2026-05-04

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

Terminated

13 enrolled

HER2-positive Breast Cancer

NCT01613482 2026-03-16

TSARINE

13 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

55 enrolled

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT04578106 2026-01-06

ELPIS

5 enrolled 7 charts

Breast Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

13 enrolled

Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

2 enrolled 6 charts

Breast Neoplasms

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

2 enrolled

Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

17 enrolled 16 charts

Breast Neoplasms, Meningeal Neoplasms

NCT04789096 2025-06-06

TUGETHER

31 enrolled

Breast Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

96 enrolled 16 charts

Breast Neoplasms

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast Neoplasms

NCT05555251 2024-12-16

CONTRAST

18 enrolled

BreastGastrointestinal

HER2-positive Breast Cancer

NCT04675827 2024-12-04

Decrescendo

139 enrolled

Breast Neoplasms

NCT00963547 2024-06-04

MK-2206-015

33 enrolled 13 charts

Breast Neoplasms

NCT02771795 2024-02-02

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Terminated

538 enrolled 9 charts

Breast Neoplasms, Neoplasms

NCT01873833 2023-10-05

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

10 enrolled 16 charts

Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

7 enrolled 10 charts

Locally Advanced Breast Cancer

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

63 enrolled 22 charts

Breast Neoplasms

NCT00004935 2023-04-18

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

175 enrolled

Breast Neoplasms

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

53 enrolled

Breast Neoplasms

NCT03931551 2023-02-22

OPHELIA

5 enrolled

Advanced Breast Cancer

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

201 enrolled 71 charts

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

7 enrolled 8 charts

Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

BreastGastrointestinalThoracic

2 enrolled 9 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT04102618 2022-08-15

AWARE-1

Phase EARLY_PHASE1 Terminated

26 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

2 enrolled 7 charts

Breast Neoplasms

NCT00810017 2022-05-19

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

2 enrolled 3 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02213042 2021-10-13

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

42 enrolled 13 charts

Breast Neoplasms

NCT02907918 2021-09-29

PALTAN

26 enrolled 8 charts

Breast Neoplasms

NCT03894007 2021-09-23

PREDIXIIHER2

6 enrolled

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

66 enrolled 40 charts

Breast Neoplasms

NCT00138125 2020-10-19

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

2 enrolled 5 charts

Breast Neoplasms

NCT00625898 2020-09-10

BETH

3,509 enrolled

Breast Neoplasms

NCT04066790 2020-05-19

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

12 enrolled

Breast Neoplasms

NCT02774681 2020-04-14

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

12 enrolled 11 charts

Breast Neoplasms

NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

6 enrolled

BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

NCT00140140 2019-11-26

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

16 enrolled 21 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02318901 2019-10-21

PembroMab

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01891357 2019-09-17

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

64 enrolled 7 charts

Carcinoma, Ductal, Breast

NCT02598310 2019-08-28

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

30 enrolled

Breast Neoplasms

NCT00130507 2019-02-26

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

14 enrolled

Breast Neoplasms

NCT01185509 2019-01-23

Trastuzumab and Vinorelbine in Advanced Breast Cancer

31 enrolled 11 charts

Breast Neoplasms

NCT01912963 2018-12-05

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

32 enrolled 15 charts

Breast Neoplasms

NCT02297230 2018-10-15

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

44 enrolled 6 charts